Friday, April 01, 2022 2:35:30 AM
Looking forward to 2022:
Thanks to the significant progress last year, we enter 2022 stronger and well-positioned for anticipated approvals. Looking ahead, we expect multiple catalysts, including:
? Yselty® for uterine fibroids:
– PUDFA target action date of September 13, 2022, as set by the FDA
– European Commission approval expected following December 2021 positive CHMP opinion
– Preparing for commercial launch
? Yselty® for endometriosis:
– Additional data from the post-treatment follow-up of the Phase 3 EDELWEISS 3 trial are
expected in 2Q 2022 and from the post-treatment follow-up of the extension study in 4Q 2022
? Ebopiprant:
– Discussing US clinical development with the FDA
? New opportunities:
– Exploring new indications, partnerships, and other strategic opportunities that enhance
ObsEva’s value and further our mission of bringing to market novel therapies that improve women’s health
? Financing: Furthering ongoing efforts to strengthen the balance sheet
Recent OBSV News
- ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin • GlobeNewswire Inc. • 04/03/2024 05:00:00 AM
- ObsEva Announces Update on Board of Directors • GlobeNewswire Inc. • 03/19/2024 06:00:00 AM
- ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023 • GlobeNewswire Inc. • 02/28/2024 06:00:00 AM
- Geneva Court Grants Temporary Moratorium to ObsEva • GlobeNewswire Inc. • 01/31/2024 06:00:00 AM
- ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals • GlobeNewswire Inc. • 11/30/2023 06:00:00 AM
- Organon Returns Ebopiprant to XOMA • GlobeNewswire Inc. • 10/27/2023 09:00:00 PM
- ObsEva Files half Year 2023 Financial Statements • GlobeNewswire Inc. • 09/27/2023 05:00:00 AM
- ObsEva Recovers Full Worldwide Rights on Nolasiban • GlobeNewswire Inc. • 07/13/2023 05:00:00 AM
- Annual General Meeting 2023 • GlobeNewswire Inc. • 06/08/2023 05:00:00 AM
- ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer • GlobeNewswire Inc. • 05/02/2023 05:00:00 AM
- ObsEva Announces Change of Central Securities Depositary • GlobeNewswire Inc. • 04/20/2023 11:00:00 AM
FEATURED Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • Apr 17, 2024 8:00 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • BLEG • Apr 16, 2024 8:30 AM